Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Teva And Allergan Finalize Generics Deal

XTALKS VITALS NEWS

Acquisition

In order to receive the FTC’s support with the deal, Teva agreed to unload 79 generic products onto 11 different companies.

Tweetables from this article:

Tweet: FTC approves $40.5 billion acquisition of Allergan’s generic drugs business by Teva Pharmaceuticals http://ctt.ec/VBj0r+FTC approves $40.5 billion acquisition of Allergan’s generic drugs business by Teva Pharmaceuticals.

Share this!

August 2, 2016 | by Sarah Massey, M.Sc.

Last week, the Federal Trade Commission (FTC) approved the $40.5 billion acquisition of Allergan’s generic drugs business by Israel-based company, Teva Pharmaceuticals. In order to receive the FTC’s support with the deal, Teva agreed to unload 79 generic products onto 11 different companies.

While Teva was already a top generics maker in many markets before the deal with Allergan, the company now expects to be in the top three in more than 40 markets worldwide. The company expects that in the next three years, the acquisition will generate more than $25 billion in revenue.

“The new Teva will be ideally positioned to realize the opportunities the global and U.S. generic markets offer,” said Erez Vigodman, chief executive of Teva. According to the FTC, Teva will soon take control of a 22 percent market share in the US.

“Although this merger combines two large sellers of generic drugs, the generic pharmaceutical industry as a whole remains relatively unconcentrated,” said a statement issued by the FTC. “Over two hundred firms sell generic drugs in the United States and the five largest suppliers account only for about half of overall generic sales.”



Teva has been given ten days to sell off the 79 drugs, some of which were already planned to be divested before the FTC made their decision. The company will be selling the rights to these drugs to a number of their competitors, including Impax Labs, Dr. Reddy’s and Mayne Pharma.

The FTC is also requiring Teva to offer third-party drugmakers long term supply contracts for the active pharmaceutical ingredients (API) manufactured by the generics company. These contracts would provide security to those companies which rely on Teva-produced APIs, preventing the generic drugmaker from cutting supply if a brand-name drug competes with their generic products.

According to Teva, the company will save $1.4 billion in the next three years as a result of reduced operational costs and tax breaks from the deal. “The transaction strongly reinforces our strategy and yields very compelling economics,” said Vigodman. “As a result, it opens a new set of possibilities for us in generics and specialty medicines.”

In anticipation of the acquisition, Teva liquidated $15 billion worth of bonds last week. The company was able to avoid taking on new debt in order to finance their deal with Allergan.


Keywords: Generics, Pharmaceuticals, Acquisition


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
New Approach Could Allow Red Blood Cells to be Manufactured

March 27, 2017 - UK researchers at the University of Bristol have developed an immortal line of early adult erythroblasts capable of continuously producing mature red blood cells.

Featured In: Biotech News


Lung Cancer Recurrence Could Be Better Detected Using Biomarker Blood Test

March 24, 2017 - The results of a recent prospective clinical trial found that a biomarker blood test could detect lung cancer recurrence a full six months before imaging methods could spot the disease.

Featured In: Biotech News


Use of Testosterone Treatments Boosted by DTC Ad Campaigns

March 24, 2017 - Those with a stake in the pharmaceutical industry often question the effectiveness of direct-to-consumer (DTC) advertising, and whether it truly influences consumers to talk to their doctors about medical conditions and perhaps even ask for drugs by name.

Featured In: Pharmaceutical Marketing News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.